Zofia T Bilinska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7875461/publications.pdf

Version: 2024-02-01

304743 118850 4,292 65 22 62 h-index citations g-index papers 67 67 67 5794 docs citations times ranked citing authors all docs

#	Article	lF	Citations
1	Good performance of the criteria of American College of Medical Genetics and Genomics/Association for Molecular Pathology in prediction of pathogenicity of genetic variants causing thoracic aortic aneurysms and dissections. Journal of Translational Medicine, 2022, 20, 42.	4.4	4
2	Tripeptidyl Peptidase 1 (TPP1) Deficiency in a 36-Year-Old Patient with Cerebellar-Extrapyramidal Syndrome and Dilated Cardiomyopathy. Life, 2022, 12, 3.	2.4	5
3	Titin-Related Dilated Cardiomyopathy: The Clinical Trajectory and the Role of Circulating Biomarkers in the Clinical Assessment. Diagnostics, 2022, 12, 13.	2.6	3
4	Impact of cardiac magnetic resonance on the diagnosis of hypertrophic cardiomyopathy - a 10-year experience with over 1000 patients. European Radiology, 2021, 31, 1194-1205.	4.5	10
5	Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23. European Heart Journal, 2021, 42, 2000-2011.	2.2	49
6	Sudden cardiac death risk in hypertrophic cardiomyopathy: comparison between echocardiography and magnetic resonance imaging. Scientific Reports, 2021, 11, 7146.	3.3	4
7	A different background of arrhythmia in siblings with a positive family history of sudden death at young age. Annals of Noninvasive Electrocardiology, 2020, 25, e12707.	1.1	3
8	Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the <i>TTN</i> Gene. Circulation: Heart Failure, 2020, 13, e006832.	3.9	75
9	A combination of quinidine/mexiletine reduces arrhythmia in dilated cardiomyopathy in two patients with R814W <i>SCN5A</i> mutation. ESC Heart Failure, 2020, 7, 4326-4335.	3.1	13
10	A Novel DSP Truncating Variant in a Family with Episodic Myocardial Injury in the Course of Arrhythmogenic Cardiomyopathy—A Possible Role of a Low Penetrance NLRP3 Variant. Diagnostics, 2020, 10, 955.	2.6	2
11	ESC EORP Cardiomyopathy Registry: realâ€ife practice of genetic counselling and testing in adult cardiomyopathy patients. ESC Heart Failure, 2020, 7, 3013-3021.	3.1	19
12	Protein Kinase C Alpha Cellular Distribution, Activity, and Proximity with Lamin A/C in Striated Muscle Laminopathies. Cells, 2020, 9, 2388.	4.1	6
13	Can Circulating Cardiac Biomarkers Be Helpful in the Assessment of LMNA Mutation Carriers?. Journal of Clinical Medicine, 2020, 9, 1443.	2.4	9
14	A Recurrent Exertional Syncope and Sudden Cardiac Arrest in a Young Athlete with Known Pathogenic p.Arg420Gln Variant in the RYR2 Gene. Diagnostics, 2020, 10, 435.	2.6	3
15	Analysis of De Novo Mutations in Sporadic Cardiomyopathies Emphasizes Their Clinical Relevance and Points to Novel Candidate Genes. Journal of Clinical Medicine, 2020, 9, 370.	2.4	12
16	The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. European Heart Journal, 2018, 39, 1784-1793.	2.2	94
17	Severe Course of Peripartum Cardiomyopathy and Subsequent Recovery in a Patient with a Novel TTN Gene-Truncating Mutation. American Journal of Case Reports, 2018, 19, 820-824.	0.8	7
18	Dilated Cardiomyopathy DueÂtoÂBLC2-Associated AthanogeneÂ3Â(BAG3)ÂMutations. Journal of the American College of Cardiology, 2018, 72, 2471-2481.	2.8	93

#	Article	IF	CITATIONS
19	Lamin missense mutations—the spectrum of phenotype variability is increasing. European Journal of Heart Failure, 2018, 20, 1413-1416.	7.1	5
20	Variable clinical presentation of glycogen storage disease type IV: from severe hepatosplenomegaly to cardiac insufficiency. Some discrepancies in genetic and biochemical abnormalities. Archives of Medical Science, 2018, 1, 237-247.	0.9	17
21	Rapid and effective response of the R222Q SCN5A to quinidine treatment in a patient with Purkinje-related ventricular arrhythmia and familial dilated cardiomyopathy: a case report. BMC Medical Genetics, 2018, 19, 94.	2.1	23
22	Sudden cardiac arrest in patients without overt heart disease: limited value of next generation sequencing. Polish Archives of Internal Medicine, 2018, 128, 721-730.	0.4	8
23	Autosomal recessive, familial, isolated dilated cardiomyopathy due to compound desmoplakin gene mutations. Polish Archives of Internal Medicine, 2018, 128, 785-787.	0.4	2
24	Homozygous truncating mutation in NRAP gene identified by whole exome sequencing in a patient with dilated cardiomyopathy. Scientific Reports, 2017, 7, 3362.	3.3	30
25	Titin Truncating Variants in Dilated Cardiomyopathy – Prevalence and Genotype-Phenotype Correlations. PLoS ONE, 2017, 12, e0169007.	2.5	63
26	Quantification of mitral regurgitation in patients with hypertrophic cardiomyopathy using aortic and pulmonary flow data: impacts of left ventricular outflow tract obstruction and different left ventricular segmentation methods. Journal of Cardiovascular Magnetic Resonance, 2017, 19, 105.	3.3	10
27	Restrictive cardiomyopathy due to novel desmin gene mutation. Kardiologia Polska, 2017, 75, 723-723.	0.6	12
28	Evidence for troponin C ($\langle i\rangle$ TNNC1 $\langle i\rangle$) as a gene for autosomal recessive restrictive cardiomyopathy with fatal outcome in infancy. American Journal of Medical Genetics, Part A, 2016, 170, 3241-3248.	1.2	37
29	Next-generation sequencing for diagnosis of thoracic aortic aneurysms and dissections: diagnostic yield, novel mutations and genotype phenotype correlations. Journal of Translational Medicine, 2016, 14, 115.	4.4	47
30	Clinical Applications for Next Generation Sequencing in Cardiology. , 2016, , 189-215.		0
31	Novel truncating desmoplakin mutation as a potential cause of sudden cardiac death in a family. Polish Archives of Internal Medicine, 2016, 126, 704-707.	0.4	2
32	A new missense mutation, p.Arg719Leu, of the beta-myosin heavy chain gene in a patient with familial hypertrophic cardiomyopathy. Minerva Cardiology and Angiology, 2016, 65, 96-102.	0.7	0
33	A study in Polish patients with cardiomyopathy emphasizes pathogenicity of phospholamban (PLN) mutations at amino acid position 9 and low penetrance of heterozygous null PLN mutations. BMC Medical Genetics, 2015, 16, 21.	2.1	28
34	Does p.Q247X in TRIM63 Cause Human Hypertrophic Cardiomyopathy?. Circulation Research, 2014, 114, e2-5.	4.5	88
35	The BAG3 gene variants in Polish patients with dilated cardiomyopathy: four novel mutations and a genotype-phenotype correlation. Journal of Translational Medicine, 2014, 12, 192.	4.4	81
36	Lamin A/C mutations in dilated cardiomyopathy. Cardiology Journal, 2014, 21, 331-342.	1.2	53

3

#	Article	IF	Citations
37	LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies. BMC Medical Genetics, 2013, 14, 55.	2.1	11
38	Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol. Pharmacogenetics and Genomics, 2013, 23, 611-618.	1.5	12
39	s A fatal outcome of thoracic aortic aneurysm in a male patient with bicuspid aortic valve. Postepy W Kardiologii Interwencyjnej, 2013, 3, 265-271.	0.2	1
40	Variants of the Lamin A/C (LMNA) Gene in Non-Valvular Atrial Fibrillation Patients. Molecular Diagnosis and Therapy, 2012, 16, 99-107.	3.8	24
41	Coronary Computed Tomographic Angiography for Prediction of Procedural and Intermediate Outcome of Bypass Grafting to Left Anterior Descending Artery Occlusion With Failed Visualization on Conventional Angiography. American Journal of Cardiology, 2012, 109, 1722-1728.	1.6	23
42	Therapeutic challenges and management of heart failure during pregnancy (part 2). Medical Science Monitor, 2012, 18, CQ9-CQ13.	1.1	0
43	Therapeutic challenges and management of heart failure during pregnancy (part I). Medical Science Monitor, 2012, 18, CQ5-CQ7.	1.1	1
44	A new c.1621 C>G, p.R541G lamin A/C mutation in a family with DCM and regional wall motion abnormalities (akinesis/dyskinesis): genotype–phenotype correlation. Journal of Human Genetics, 2011, 56, 83-86.	2.3	12
45	Genetic and ultrastructural studies in dilated cardiomyopathy patients: a large deletion in the lamin A/C gene is associated with cardiomyocyte nuclear envelope disruption. Basic Research in Cardiology, 2010, 105, 365-377.	5.9	79
46	The protective effect of influenza vaccination on the clinical course of coronary disease in patients with acute coronary syndromes treated by primary PCI $\hat{a} \in \text{``a report from FLUCAD study. Postepy W Kardiologii Interwencyjnej, 2010, 1, 6-11.}$	0.2	3
47	Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2010, 31, 2715-2726.	2.2	408
48	Autophagy in transition from hypertrophic cardiomyopathy to heart failure. Journal of Electron Microscopy, 2010, 59, 181-183.	0.9	40
49	Dilated cardiomyopathy with profound segmental wall motion abnormalities and ventricular arrhythmia caused by the R541C mutation in the LMNA gene. International Journal of Cardiology, 2010, 144, e51-e53.	1.7	10
50	Platelet reactivity on aspirin, clopidogrel and abciximab in patients with acute coronary syndromes and reduced estimated glomerular filtration rate. Thrombosis Research, 2010, 125, 67-71.	1.7	9
51	Baseline Clinical Characteristics and Midterm Prognosis of STEâ€ACS and NSTEâ€ACS Patients with Normal Coronary Arteries. Annals of Noninvasive Electrocardiology, 2009, 14, 4-12.	1.1	3
52	Specific contribution of lamin A and lamin C in the development of laminopathies. Experimental Cell Research, 2008, 314, 2362-2375.	2.6	25
53	Obliteration of cardiomyocyte nuclear architecture in a patient with LMNA gene mutation. Journal of the Neurological Sciences, 2008, 271, 91-96.	0.6	22
54	Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. European Heart Journal, 2008, 29, 1350-1358.	2.2	211

#	Article	IF	CITATIONS
55	Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. European Heart Journal, 2007, 29, 270-276.	2.2	2,280
56	Dilated cardiomyopathy caused by LMNA mutations. Clinical and morphological studies. Kardiologia Polska, 2006, 64, 812-9; discussion 820-1.	0.6	8
57	Cumulative incidence of coronary lesions with vulnerable characteristics in patients with stable angina pectoris: an intravascular ultrasound and angiographic study. International Journal of Cardiology, 2005, 102, 201-206.	1.7	7
58	In vivo and in vitro examination of the functional significances of novel lamin gene mutations in heart failure patients. Journal of Medical Genetics, 2005, 42, 639-647.	3.2	87
59	Usefulness of 1H MR spectroscopy in the evaluation of myocardial metabolism in patients with dilated idiopathic cardiomyopathy. Academic Radiology, 2003, 10, 1187-1192.	2.5	11
60	Familial dilated cardiomyopathy: evidence for clinical and immunogenetic heterogeneity. Medical Science Monitor, 2003, 9, CR167-74.	1.1	1
61	Unexpected eosinophilic myocarditis in a young woman with rapidly progressive dilated cardiomyopathy. International Journal of Cardiology, 2002, 86, 295-297.	1.7	6
62	Determinants of prognosis in nonischemic dilated cardiomyopathy. Journal of Cardiac Failure, 1996, 2, 77-85.	1.7	64
63	Increased frequency of organâ€specific cardiac antibodies in healthy relatives of patients with dilated cardiomyopathy: Evidence for autoimmunity in polish families. Clinical Cardiology, 1996, 19, 794-798.	1.8	6
64	Organ-specific cardiac autoantibodies in dilated cardiomyopathy. European Heart Journal, 1995, 16, 1907-1911.	2.2	8
65	Left ventricular enlargement is common in relatives of patients with dilated cardiomyopathy. Journal of Cardiac Failure, 1995, 1, 347-353.	1.7	3